2025
Incidence and Risk Factors for Steroid-associated Osteonecrosis in Children and Adolescents: A Systematic Review of the Literature
Johnson T, Naz H, Taylor V, Farook S, Hofmann G, Harbacheck K, Pham N, Smith S, Chao K, Lee T, Goodman S, Shea K. Incidence and Risk Factors for Steroid-associated Osteonecrosis in Children and Adolescents: A Systematic Review of the Literature. Journal Of Pediatric Orthopaedics 2025, 45: 337-347. PMID: 40078093, DOI: 10.1097/bpo.0000000000002919.Peer-Reviewed Original ResearchConceptsSystematic reviewClinical decision-makingCohort studyRisk factorsSteroid-associated osteonecrosisControlled TrialsNon-Hispanic raceCochrane Central Registry of Controlled TrialsMeta-analyses guidelinesPediatric orthopaedic surgeonsCentral Registry of Controlled TrialsRegistry of Controlled TrialsProspective cohort studyStandard clinical pathwayBody mass indexComprehensive systematic reviewRandomized Controlled TrialsCochrane Central RegistryRetrospective cohort studyScreened titlesFunctional disabilityGenetic risk factorsSystemic corticosteroid exposureClinical pathwayYears of age
2021
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors
Long AS, Zhang AD, Meyer CE, Egilman AC, Ross JS, Wallach JD. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors. JAMA Network Open 2021, 4: e215731. PMID: 33956134, PMCID: PMC8103227, DOI: 10.1001/jamanetworkopen.2021.5731.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsSafety end pointEnd pointClinical trialsDrug pairsPrimary end point resultsEnd point resultsImproved efficacyEfficacy end pointCochrane Central RegistrySeparate end pointsSingle-enantiomer drugsSingle enantiomer formulationPrimary efficacySecondary efficacyControlled TrialsOvid EmbaseOvid MEDLINESuperior efficacyDrug AdministrationCentral RegistrySystematic reviewMore efficacyTrialsRacemic drugs
2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply